MedPath

Using Sensors to Measure Drug Concentrations in Exhaled Breath

Conditions
Mental Disorder
Registration Number
NCT04071145
Lead Sponsor
Nadav Goldental
Brief Summary

The use of blood tests to measure drug concentrations in psychiatric patients is often a crucial part of monitoring and evaluating the course of treatment. Such tests are commonly conducted as part of official protocols, and patients are often tested on a weekly basis.

The current study aims to examine the possibility of using a novel, non-invasive device to measure drug concentrations in exhaled breath as an alternative to blood tests. The device, SniffPhone, uses sensors to detect and measure volatile organic compounds (VOCs) in exhaled breath, and features a small and portable design. Sniff Phone has been previously approved for use in clinical trials and has been used successfully to screen for particular types of cancer and other diseases.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria
  • Proper ability to give informed consent
  • Psychiatric patients undergoing treatment at Sheba Medical Center
  • Patients with treatment plans that require therapeutic drug monitoring
Exclusion Criteria
  • Involuntary psychiatric hospitalization
  • Pregnancy

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Correlation between drug concentration and volatile organic compounds VOC concentrationsUp to 6 months

Correlation between drug concentration (as measured in blood test) and VOCs (hexanone acetic acid, heptane, hexanal, 3-heptanone, hexanoic acid, heptanal and nonanal) measured using Sniff Phone.

Detection of drug type and concentration in volatile organic compounds (VOCs) profileUp to 6 months

Detection of drug type and concentration in VOCs profile (measured using Sniff Phone)

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath